Theodore Robnett, MD
OncoLink Assistant Editor
Ultima Vez Modificado: 1 de noviembre del 1999
Presenter: Ming Fan, M.D.
Affiliation: Duke University Medical Center
Radiation induced pulmonary changes can cause serious, even life-threatening problems in patients whose lung function is already compromised by tumor burden and smoking. There are many studies which qualitatively document pulmonary toxicity relative to dosing parameters. The present study attempts to predict quantitative changes in PFTs based on these parameters.
Ninety-six of 185 patients (68% with lung cancer) were prospectively evaluated with PFTs prior to and 6 months following RT. Thirty-four patients received chemotherapy. Criteria for selection included no evidence of intra-thoracic recurrence at follow up. Predicted PFTs were based on the summation of products derived from dose volume histograms (DVHs) and reduced lung volumes. An alternate formula used perfused lung volumes (DFH) instead of total lung volumes. Predicted and measured changes were compared using linear regression. A multivariate analysis on clinical variables including age, tumor site and baseline PFTs was also performed.
ASTRO coverage is sponsored, in part, by Varian Medical Systems, Inc.
Oct 4, 2013 - For women with stage IIIB squamous cervical cancer, cisplatin added to radiotherapy plus high-dose-rate brachytherapy is associated with improved disease-free survival, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 22 to 25 in Atlanta.